Tax Reform Takes Its Toll: AbbVie Having Second Thoughts About Shire
This article was originally published in The Pink Sheet Daily
The $54 billion acquisition could fall through now that AbbVie can’t reap the rewards of a tax inversion, calling into question the value of Shire and its rare disease portfolio.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.